Trials / Recruiting
RecruitingNCT05467189
Antineoplastic Drugs in Elderly Patients
Population Pharmacokinetics, Effectiveness and Safety of Antineoplastic Drugs in Elderly Patients
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Shandong University · Academic / Other
- Sex
- All
- Age
- 65 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in elderly patients and recommend optimized dosage regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs) | As part of routine treatment. |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2028-03-30
- Completion
- 2028-06-30
- First posted
- 2022-07-20
- Last updated
- 2022-07-20
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05467189. Inclusion in this directory is not an endorsement.